ViroPharma price target raised to $38 from $30 at JMP Securities JMP Securities increased its target on ViroPharma as the firm believes that the company's new diversification strategy will significantly lower its tax rate and create opportunities to develop new drugs. The firm reiterates an Outperform rating on the stock.
News For VPHM From The Last 14 Days
Check below for free stories on VPHM the last two weeks.
